ImmunityBio shared a post on X:
“At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform.
This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. ”
Other articles about ImmunityBio on OncoDaily.